ST. JOSEPH, Mich., April 15 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that The Scripps Translational Science Institute has joined the MetaMiner Cardiac Consortium. The goal of the Consortium is to build the first systems biology and pathway analysis platform for cardiovascular diseases in the world. The Consortium members will vote on deliverables that will include disease specific pathway maps and networks built by experts in the field. GeneGo will also develop relevant ontologies for cardiovascular diseases and drugs. The MetaMiner environment will also serve as a repository for OMICs and other experimental data.
"We are very excited to have The Scripps Translational Science Institute, lead by Dr. Eric Topol, Director, as a member. He is a world renowned expert in this field and will provide strong leadership for the project," said Julie Bryant, GeneGo's VP of Business development. "The cardiovascular disease area is complex and a challenging field. We believe that MetaMiner Cardiac will have an impact on both basic research and drug discovery in this area."
GeneGo develops systems biology technology for life science research.
The original computational MetaDiscovery(TM) platform allows an integration
and expert analysis of different kinds of experimental data (mRNA
expression, proteomics, metabolomics, microRNA assays and other phenotypic
data) and relevant bioactive chemistry (metabolites, drugs, other
xenobiotics) within the framework of curated biological pathways and
networks. GeneGo's flagship product, MetaCore 4.7(TM), assists
pharmaceutical scientists in the areas of target selection and validation,
identification of biomarkers for disease states and toxicology. The second
product, MetaDrug 4.7(TM) is designed for prediction of human metabolism,
toxicity and biological effects for novel small molecules compounds.
MetaBase(TM) represents the knowledge base for MetaCore.
|SOURCE GeneGo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved